Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633486 | 0.90 | DPP4 (0.51) | L3MBTL3L3MBTL1OPRM1MEN1KMT2A | |
| SCHEMBL3630899 | 0.86 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1OPRM1MEN1KMT2A | |
| SCHEMBL6776735 | 0.83 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1OPRM1MEN1KMT2A | |
| SCHEMBL8476760 | 0.83 | CYP2D6 (0.53) | OPRM1MEN1KMT2ACHRM2ADRA2A | |
| SCHEMBL8477673 | 0.83 | ACHE (0.51) | OPRM1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL3629712 | 0.82 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1OPRM1MEN1KMT2A | |
| SCHEMBL13597004 | 0.82 | L3MBTL1 (0.56) | L3MBTL3L3MBTL1OPRM1MEN1KMT2A | |
| SCHEMBL3458578 | 0.82 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1OPRM1MEN1KMT2A | |
| SCHEMBL8472991 | 0.82 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1OPRM1MEN1KMT2A | |
| SCHEMBL7972891 | 0.82 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1OPRM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563782-B2 | Optically active stereoisomer of efonidipine analogs; R-configuration of the 4-position on dihydropyridine ring; kidney insufficiency; hypercardia; congestive heart failure; cardiomyopathy; arterial sclerosis; antifibrillatory/antiarrhythmia agents; cardiovascular disorders; antiedemic/antiinflammatory | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20070010490-A1 | T-type calcium channel blockers | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
| US-5872115-A | COMPOUNDS FOR TREATMENT OF HYPERCHOLESTEROLEMIA, ISCHEMIC HEART DISEASE, CEREBROVASCULAR DISEASE OR ATHEROSCLEROSIS | GRELAN PHARMACEUTICAL CO. LTD. (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0742208-A1 | 2-Ureido-benzamide derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010490-A1 | T-type calcium channel blockers | CACNA1E, RYR2, RYR1 | L3MBTL3 2979/4885L3MBTL1 3118/4885OPRM1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.